Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Not yet recruiting	Phase 2	2019-11-06		NCT04153734

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Kobe Minimally Invasive Cancer Center	1
Merck Sharp & Dohme LLC	650

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.

Clinical trials